Company Filing History:
Years Active: 1987-1990
Title: Innovations by Wolfgang Frechinger in Blood Plasma Pathogen Inactivation
Introduction
Wolfgang Frechinger, an esteemed inventor based in Vienna, Austria, has made significant contributions to the field of medical technology with his innovative approaches to blood plasma treatment. With two patents to his name, Frechinger's work focuses on inactivating filterable pathogens in blood products, thereby enhancing their safety and efficacy.
Latest Patents
Frechinger's latest patents detail groundbreaking methods for inactivating pathogens in blood plasma and blood products. One of his patents outlines a method that utilizes elevated temperatures to effectively inactivate reproducible filterable pathogens in blood plasma. This technique involves heat treatment in a solid state within a closed inactivation container, utilizing specific amounts of water and organic compounds to ensure the effectiveness of the process. The particulars include maintaining a water content of 0.08 to 0.40 and a concentration of organic compounds in the gaseous phase between 0.01 to 10 grams per liter of container volume.
Additionally, Frechinger's second patent describes an alternative approach involving the heat treatment of blood products. In this method, the presence of hydroxyl group-containing compounds, such as water, methanol, ethanol, or mannitol, is crucial. The process can be performed at temperatures of up to 121 degrees Celsius, with heat treatment durations ranging from 1 second to 100 hours. This innovative approach aims to inactivate viruses while producing valuable blood products, including enzymes and immunoglobulins, all while ensuring the destruction of any potential pathogens.
Career Highlights
Wolfgang Frechinger currently works at Immuno Aktiengesellschaft für Chemisch-medizinische Produkte, a company dedicated to developing innovative solutions for medical products. His role involves pushing the boundaries of medical technology to create safer blood products through his exceptional methods of pathogen inactivation.
Collaborations
Frechinger has collaborated with renowned colleagues in the field, including Johann J. Eibl and Otto Schwarz. Together, they work towards advancing medical research and developing technologies that improve the safety of blood transfusions and related therapies.
Conclusion
Wolfgang Frechinger's contributions to pathogen inactivation in blood plasma products are a significant advancement in medical technology. His inventions not only enhance the safety of blood products but also underscore the importance of innovation in healthcare solutions. Through his continued work at Immuno Aktiengesellschaft für Chemisch-medizinische Produkte and his impactful collaborations, Frechinger is paving the way for future advancements in the medical field.